Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA half-time (representing rate to PSA nadir after ADT), the incidence of, and time to CRPC occurrence, and cause-specific mortality rates were determined during the 3-10 years follow-up.
|
25731771 |
2015 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result, the phosphorylation of MET was observed in 56% (35 of 62 cases) and positively correlated with worsening PSA relapse rate in a group of ADT-treated patients (P = 0.0445), suggesting significant correlation with CRPC.
|
25862631 |
2015 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although SB939 was tolerable at the dose/schedule given, and showed declines in CTC in the majority of evaluable patients, it did not show sufficient activity based on PSA RR to warrant further study as a single agent in unselected patients with CRPC.
|
25983041 |
2015 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patient 2 was a 74-year-old man with castration-resistant prostate cancer who was diagnosed with RA during chemotherapy and a gradual increase in prostate-specific antigen (PSA) level.
|
27044355 |
2016 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present review, we ascertain the PSA dynamics and the mechanisms of the development of CRPC to assist in optimal utilization of the new treatments for mCRPC.
|
27270339 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RNA levels of AR-V7 and PSA in peripheral blood collected before treatment were quantified using droplet digital-PCR in retrospective cohorts treated with abiraterone acetate (N = 81) or enzalutamide (N = 51) for CRPC.
|
27489290 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The majority of CRPC bone metastases (80%) was defined as AR-driven based on PCA analysis and high expression of the AR, AR co-regulators (FOXA1, HOXB13), and AR-regulated genes (KLK2, KLK3, NKX3.1, STEAP2, TMPRSS2); 20% were non-AR-driven.
|
27497761 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The predictor model included PSA, alkaline phosphatase and albumin as independent prognostic factors of the time required to progress to CRPC in patients who had received ADT.
|
27837416 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the other hand, several studies showed a high prostate specific antigen (PSA) response with low-dose dexamethasone in castration-resistant prostate cancer (CRPC) patients.
|
28042138 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Cox proportional hazards model and a C-index were used to investigate associations between overall survival (OS) and BSI, and patient age, prostate-specific antigen, time to CRPC, previous docetaxel use, and pain.
|
28110835 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.
|
28126272 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS).
|
28151974 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DNA double-strand breaks were induced in cancer cells within 24 hours after radium-223 treatment, and PSA levels were significantly lower 72 hours after treatment, providing further evidence of the antitumor effects.<b>Conclusions:</b> Taken together, radium-223 therapy exhibits a dual targeting mode-of-action that induces tumor cell death and suppresses tumor-induced pathologic bone formation in tumor microenvironment of osseous CRPC growth in mice.<i></i>.
|
28364014 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To examine whether prostate-specific antigen doubling time (PSADT) correlates with metastases, all-cause mortality (ACM), and prostate cancer-specific mortality (PCSM) and to identify PSADT thresholds that can be used clinically for risk stratification in men with M0 castration-resistant prostate cancer (CRPC).
|
28371163 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to assess PSA surge phenomenon in castration-resistant prostate cancer (CRPC) patients treated with abiraterone and to correlate those variations with long-term treatment outcome.
|
28429372 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Second-line hormonal therapy (eg, antiandrogens, CYP17 inhibitors) may be considered in patients with nonmetastatic CRPC at high risk for metastatic disease (rapid prostate-specific antigen doubling time or velocity) but otherwise is not suggested.
|
28441112 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A phase I study recently reported that seviteronel, a CYP17 lyase-selective inhibitor, ædemonstrated a sustained reduction in prostate-specific antigen in a patient with CRPC, and another study showed seviteronel's direct effects on AR function.
|
28463227 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intratumoral and subcutaneous injections of HVJ-E are feasible and PSA response was observed in a subgroup of CRPC patients.
|
28497777 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cause specific survival and time to prostate specific antigen (castrate resistant prostate cancer) progression were analyzed.
|
28552710 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of this study suggested the A-E sequence had longer combined PSA and total PSA-PFS compared to the E-A sequence in patients with CRPC.
|
28557065 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Age, PSA level, and BSI were found to be significant predictive factors for time to CRPC in patients with mHSPC.
|
28609769 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metastatic castration resistant prostate cancer with low baseline prostate specific antigen represents an early stage in the natural history of castration resistant prostate cancer progression (low volume disease), low prostate specific antigen producing disease or disease that is less dependent on androgen receptor biology (high volume disease).
|
28736322 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Those with an early prostate specific antigen doubling time of 3 to 8.9 months were at increased risk for castration resistant prostate cancer (HR 3.56, p = 0.015), all cause mortality (HR 1.67, p = 0.006) and prostate cancer specific mortality (HR 3.17, p = 0.044) but not metastases (p = 0.13).
|
28870860 |
2018 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cox proportional-hazards regression models were calculated to estimate effects of these variables on the time of progression to CRPC.On univariate and multivariate analyses, the presence of distant metastasis before ADT (hazard ratio [HR] 6.030, 95% confidence interval (CI) 3.229-11.263, P = .001), higher PSA nadir (HR 1.185, 95% CI 1.080-1.301, P = .001), a velocity of PSA decline >11 ng/mL per month (HR 2.124, 95% CI 1.195-3.750, P = .001), and a time to PSA nadir ≤9 months (HR 0.276, 95% CI 0.162-0.469, P = .004) were significantly associated with an increased risk of progression to CRPC.Patients with a rapidly decreasing PSA level in the initial phase of ADT are more likely to progress to CRPC.
|
28885333 |
2017 |
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
|
28905815 |
2019 |